Compounding Center to Pay $200 Million for Meningitis Outbreak
The former New England Compounding Center will pay $200 million to victims and creditors for the 2012 outbreak of meningitis that killed 64.
A bankruptcy reorganization plan approved by US Bankruptcy Court Judge Henry Boroff on May 19, 2015 will result in New England Compounding Center paying $200 million to victims and creditors involved in the 2012 meningitis outbreak that left 64 people dead. The drug responsible for the deaths, a steroid used to treat back pain that was contaminated with fungal meningitis, was also linked to 750 people who were sickened, according to Reuters. The Massachusetts pharmacy filed for Chapter 11 bankruptcy in December 2012, seven months after the meningitis outbreak began.
The company’s chief pharmacist is one of two people implicated in the outbreak and charged with second-degree murder. Of the $200 million, $18 million will be seized from the chief pharmacist and the company’s founders. In December 2014, 14 people were indicted for the outbreak, including charges of “racketeering, mail fraud, conspiracy, contempt, structuring, and violations of the Food, Drug, and Cosmetic Act,” according to an article from Modern Healthcare. Since the outbreak, FDA has tightened its role in inspecting compounding facilities following a November 2012 statement from former FDA commissioner, Margaret Hamburg.
Sources: Reuters
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.
